DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder

Journal of Psychiatric Research

Volumn 45, Issue 11, 2011, Pages 1432-1438

  Nohesara, Shabnam ^a   Ghadirivasfi, Mohammad ^a   Mostafavi, Sahar ^b   Eskandari, Mohammad Reza ^c   Ahmadkhaniha, HamidReza ^a   Thiagalingam, Sam ^b   Abdolmaleky, Hamid Mostafavi ^a,b,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Bipolar disorder; DNA Methylation; Epigenetic biomarker; MB COMT; Saliva; Schizophrenia

Indexed keywords

BETA ACTIN; CATECHOL METHYLTRANSFERASE; DNA;

ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELATIVE; SALIVA; SCHIZOPHRENIA;

EID: 80053988998     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.06.013     Document Type: Article

References (39)

1. Abdolmaleky H.M., Smith C.L., Faraone S.V., Shafa R., Stone W., Glatt S.J., et al. Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2004, 127(1):51-59.
2. Abdolmaleky H.M., Thiagalingam S., Wilcox M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. American Journal of Pharmacogenomics 2005, 5(3):149-160. [Review].
3. Abdolmaleky H.M., Cheng K.H., Russo A., Smith C.L., Faraone S.V., Wilcox M., et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2005, 134(1):60-66.
4. Abdolmaleky H.M., Cheng K.H., Faraone S.V., Wilcox M., Glatt S.J., Gao F., et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Human Molcular Genetics 2006, 15(21):3132-3145.
5. Abdolmaleky H.M., Zhou J.-R., Thiagalingam S., Smith C.L. Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics. Pharmacogenomics 2008, 9(12):1809-1823.
6. Abdolmaleky H.M., Smith C.L., Zhou J.-R., Thiagalingam S. Epigenetic modulation of reelin function in schizophrenia and bipolar disorder. Reelin Glycoprotein, biology, structure and roles in health and disease 2008, 365-384. Springer, USA. S.H. Fatemi (Ed.).
7. Abdolmaleky H.M., Ahmadkhaniha H.R., Nohesara S., Smith C.L. Epigenetic and genetic aberrations of the brain dopaminergic system in schizophrenia and bipolar disorder: achievements and Prospective. Iranian Journal of Psychiatry and Behavioral Sciences 2008, 2(1):4-13.
8. Abdolmaleky H.M., Smith C.L., Zhou J.-R., Thiagalingam S. Epigenetic alterations of the dopaminergic system in major psychiatric disorders. Pharmacogenomics in drug discovery and Development. Methods in molecular Biology 2008, 187-212. Humana Press Inc. J. Walker, Q. Yan (Eds.).
9. Abdolmaleky H.M., Yaqubi S., Papageorgis P., Lambert A.W., Ozturk S., Sivaraman V., et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophrenia Research 2011, 129(2-3):183-190.
10. Ballmaier M., Zoli M., Leo G., Agnati L.F., Spano P. Preferential alterations in the mesolimbic dopamine pathway of heterozygous reeler mice: an emerging animal- based model of schizophrenia. European Journal of Neuroscience 2002, 15(7):1197-1205.
11. Blasi G., Mattay V.S., Bertolino A., Elvevag B., Callicott J.H., Das S., et al. Effect of catechol-O- methyltransferase val158met genotype on attentional control. Journal of Neuroscience 2005, 25(20):5038-5045.
12. Bruder G.E., Keilp J.G., Xu H., Shikhman M., Schori E., Gorman J.M., et al. Catechol-O-Methyltransferase (COMT) genotypes and working memory: associations with differing cognitive Operations. Biological Psychiatry 2005, 58(11):901-907.
13. Chen X., Wang X., O'Neill A.F., Walsh D., Kendler K.S. Variants in the catechol-o- methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Molecular Psychiatry 2004, 9(10):962-967.
14. De Frias C.M., Annerbrink K., Westberg L., Eriksson E., Adolfsson R., Nilsson L.G. Catechol O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults. Journal of Cognitive Neuroscience 2005, 17(7):1018-1025.
15. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. Journal of Neural Transmission 1992, (suppl. 36):61-89.
16. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences U S A 2001, 98(12):6917-6922.
17. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophrenia Bulletin 2009, 35(3):528-548.
18. Galderisi S., Maj M., Kirkpatrick B., Piccardi P., Mucci A., Invernizzi G., et al. Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 2005, 52(2):83-89.
19. Ghadirivasfi M., Nohesara S., Ahmadkhaniha H.-R., Eskandari M.-R., Thiagalingam S., Abdolmaleky H.M. Hypomethylation of serotonin receptor type-2 (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2011, 156(5):536-545.
20. Glatt S.J., Faraone S.V., Tsuang M.T. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. American Journal of Psychiatry 2003, 160:469-476.
21. Grayson D.R., Jia X., Chen Y., Sharma R.P., Mitchell C.P., Guidotti A., et al. Reelin promoter hypermethylation in schizophrenia. Proceedings of the National Academy of Sciences U S A 2005, 102(26):9341-9346.
22. Kunugi H., Vallada H.P., Sham P.C., Hoda F., Arranz M.J., Li T., et al. Catechol-O-methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiply affected families. Psychiatric Genetics. 1997, 7(3):97-101.
23. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6(3):243-250.
24. Munafo M.R., Bowes L., Clark T.G., Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Molecular Psychiatry 2005, 10(8):765-770.
25. Nishikawa S., Goto S., Yamada K., Hamasaki T., Ushio Y. Lack of Reelin causes malpositioning of nigral dopaminergic neurons: evidence from comparison of normal and Reln(rl) mutant mice. Journal of Comparative Neurology 2003, 461:166-173.
26. Petronis A. The genes for major psychosis: aberrant sequence or regulation?. Neuropsychopharmacology 2000, 23(1):1-12.
27. Pooley E.C., Fineberg N., Harrison P.J. The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. Molecular Psychiatry 2007, 12(6):556-561.
28. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. International Schizophrenia Consortium. Nature 2009, 460(7256):748-752.
29. Qian Q., Wang Y., Zhou R., Li J., Wang B., Glatt S., et al. Family-based and case-control association studies of catechol-O-methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism. American Journal of Medical Genetics (Neuropsychiatric Genetics) 2003, 118B:103-109.
30. Rosa A., Peralta V., Cuesta M.J., Zarzuela A., Serrano F., Martinez-Larrea A., et al. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. American Journal of Psychiatry 2004, 161:1110-1112.
31. Sadock B., Sadock V. Kaplan and Sadock's Comprehensive Textbook of psychiatry 2009, vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA. 9 ed.
32. Shifman S., Bronstein M., Sternfeld M., Pisante A., Weizman A., Reznik I., et al. COMT: a common susceptibility gene in bipolar disorder and schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2004, 128(1):61-64.
33. Sodhi M.S., Sanders-Bush E. Serotonin and brain development. International Review of Neurobiology 2004, 59:111-174. [Review].
34. Stefanis N.C., van Os J., Avramopoulos D., Smyrnis N., Evdokimidis I., Stefanis C.N. Effect of COMT Val158Met polymorphism on the Continuous performance test, Identical pairs Version: tuning rather than improving performance. American Journal of Psychiatry 2005, 162(9):1752-1754.
35. Tenhunen J., Salminen M., Lundstrom K., Kiviluotot T., Savolainen R., Ulmanen I. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. European Journal of Biochemistry 1994, 223(3):1049-1059.
36. Wang G.J., Volkow N.D., Fowler J.S., Ding Y.S., Logan J., Gatley S.J., et al. Comparison of two pet radioligands for imaging extrastriatal dopamine transporters in human brain. Life Sciences 1995, 57(14):PL187-191.
37. Weinberger D.R., Berman K.F., Zec R.F. Physiologic Dysfunction of Dorsolateral prefrontal cortex in schizophrenia. Archives of General Psychiatry 1986, 43(2):114-124.
38. Williams H.J., Glaser B., Williams N.M., Norton N., Zammit S., Macgregor S., et al. No association between schizophrenia and polymorphisms in COMT in two large samples. American Journal of Psychiatry 2005, 162(9):1736-1738.
39. Wessa M., Linke J. Emotional processing in bipolar disorder: behavioural and neuroimaging findings. International Review of Psychiatry 2009, 21(4):357-367.